Drugs / Tezosentan
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01094067 | Sep → Dec 2010 | pulmonary arterial hypertension | Idorsia Pharmaceuticals Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01077297 | Aug → Nov 2010 | pulmonary arterial hypertension | Idorsia Pharmaceuticals Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 33 trials · 3 missed | ||||||
| Phase 3 | NCT00458276 | Apr 2007 → Feb 2008 | heart disorder, pulmonary hypertension | Idorsia Pharmaceuticals Ltd. | Terminated | Missed primary |
| Phase 3 | NCT00525707 | Apr 2003 → Jan 2005 | symptomatic heart failure | Idorsia Pharmaceuticals Ltd. | Completed | Missed primary |
| Phase 3 | NCT00524433 | Apr 2003 → Jan 2005 | symptomatic heart failure | Idorsia Pharmaceuticals Ltd. | Completed | Missed primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tezosentan | “5 mg/h intravenously, Tezosentan” NCT01094067 ↗ |
| Known as | ACT-050089 | “Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.” NCT00458276 ↗ |
| Known as | Ro 61-0612 | “Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.” NCT00458276 ↗ |
| Known as | Veletri | ChEMBL registry synonym — accepted as the source's own label CHEMBL61780 ↗ |
| Action | Inhibit | “Tezosentan is an investigational intravenous drug that blocks the endothelin receptors.” NCT00458276 ↗2“Endothelin receptor ET-A antagonist” CHEMBL61780 ↗ “Endothelin receptor ET-B antagonist” CHEMBL61780 ↗ |
| Modality | Small molecule | — CHEMBL61780 ↗ |
| Route | Intravenous | “Intravenous tezosentan (5 mg/h) during surgery and up to 24 hours afterwards (1 mg/h), or matched placebo.” PMID 23523254 ↗ Mar 2013 |
| Target | EDNRA | “Endothelin receptor ET-A antagonist” CHEMBL61780 ↗ |
| Target | EDNRB | “Endothelin receptor ET-B antagonist” CHEMBL61780 ↗ |